Evidence map›Paper›PMID 25902361›Full record

ArticleVaccine2015

Programming the composition of polymer blend particles for controlled immunity towards individual protein antigens.

Xi Zhan, Hong Shen

Abstract read
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xi ZhanDepartment of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA.
Hong ShenElsa Biologics, LLC, Box 25725, WA 98165, USA. Electronic address: hong.shen@elsa-biologics.com.
Biolog (United States) · USUniversity of Washington · US

Funding

Engineering antiviral innate immunity for safe and effective microbicidesR33AI088597 · NIAID · UNIVERSITY OF WASHINGTON · PI BANEYX, FRANCOIS C · 2012 to 2014
$1.1M
Engineering antiviral innate immunity for safe and effective microbicidesR21AI088597 · NIAID · UNIVERSITY OF WASHINGTON · PI SHEN, HONG · 2010 to 2011
$384k
NIAID NIH HHS AI088597NIAID NIH HHS R21 AI088597NIAID NIH HHS R33 AI088597
6 · The paper itself

Abstract

In order for a more precise control over the quality and quantity of immune responses stimulated by synthetic particle-based vaccines, it is critical to control the colloidal stability of particles and the release of protein antigens in both extracellular space and intracellular compartments. Different proteins exhibit different sizes, charges and solubilities. This study focused on modulating the release and colloidal stability of proteins with varied isoelectric points. A polymer particle delivery platform made from the blend of three polymers, poly(lactic-co-glycolic acid) (PLGA) and two random pH-sensitive copolymers, were developed. Our study demonstrated its programmability with respective to individual proteins. We showed the colloidal stability of particles at neutral environment and the release of each individual protein at different pH environments were dependent on the ratio of two charge polymers. Subsequently, two antigenic proteins, ovalbumin (OVA) and Type 2 Herpes Simplex Virus (HSV-2) glycoprotein D (gD) protein, were incorporated into particles with systematically varied compositions. We demonstrated that the level of in vitro CD8(+) T cell and in vivo immune responses were dependent on the ratio of two charged polymers, which correlated well with the release of proteins. This study provided a promising design framework of pH-responsive synthetic vaccines for protein antigens of interest.

Indexed as

AnimalsAntigensCD8-Positive T-LymphocytesColloidsDrug CarriersDrug StabilityFemaleHydrogen-Ion ConcentrationIsoelectric PointMice, Inbred C57BLMolecular WeightPolymersProteinsVaccines, SubunitVaccines, SyntheticAntigensColloidsDrug CarriersPolymersProteinsVaccines, SubunitVaccines, SyntheticControlled releaseHerpes simplex virusespH-sensitive particlesSubunit vaccinesViral infections

Identifiers

PMID25902361
PMCPMC4461874
OpenAlexW2038782350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.